How Gut Peptide Hormones Control Appetite and Drive Obesity Treatment Advances
Gut peptide hormones are central to appetite regulation, and dual or triple receptor agonist drugs targeting these peptides show additive weight loss benefits in early clinical trials.
Quick Facts
What This Study Found
Combining multiple gut peptide receptor agonists (dual or triple) produces additive weight loss and glycemic improvement, replicating the hormonal changes seen after bariatric surgery.
Key Numbers
Covers ghrelin, GLP-1, PYY, GIP, CCK, oxyntomodulin changes in obesity and post-surgery; dual/triple agonists in early trials
How They Did This
Narrative review of published literature on gut hormone physiology, adaptations in obesity, and emerging pharmacological therapies.
Why This Research Matters
Understanding why gut hormones change in obesity and after weight loss explains both why diets fail and why bariatric surgery succeeds, guiding development of next-generation weight loss drugs.
The Bigger Picture
This review contextualizes the rapid development of GLP-1-based and multi-target weight loss drugs, explaining the gut hormone science behind the revolutionary shift in obesity treatment.
What This Study Doesn't Tell Us
Narrative review without systematic methodology. Many dual/triple agonist data cited were from early-phase trials.
Questions This Raises
- ?Which combination of gut peptide targets produces the best weight loss with fewest side effects?
- ?Can gut hormone-based therapies fully replicate bariatric surgery's metabolic benefits?
- ?Do gut hormone changes after weight loss eventually normalize?
Trust & Context
- Key Stat:
- Multi-target Dual and triple gut peptide receptor agonists show additive weight loss benefits in early clinical trials
- Evidence Grade:
- Comprehensive narrative review with strong mechanistic basis but some cited therapies still in early development.
- Study Age:
- Published in 2020. The multi-agonist approach described has since advanced, with tirzepatide (dual GIP/GLP-1 agonist) receiving FDA approval.
- Original Title:
- The Implication of Gut Hormones in the Regulation of Energy Homeostasis and Their Role in the Pathophysiology of Obesity.
- Published In:
- Current obesity reports, 9(3), 255-271 (2020)
- Authors:
- Koliaki, Chrysi, Liatis, Stavros, Dalamaga, Maria(5), Kokkinos, Alexander
- Database ID:
- RPEP-04910
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Why does weight come back after dieting?
After weight loss, gut hormones change in ways that actively promote weight regain. Hunger hormones increase, satiety signals decrease, and the body fights to restore its previous weight. This is why purely behavioral approaches often fail long-term.
What are dual and triple agonist weight loss drugs?
These medications simultaneously activate receptors for two or three gut hormones, such as GLP-1 and GIP together. By targeting multiple pathways at once, they produce greater weight loss than single-target drugs, mimicking the hormonal changes seen after bariatric surgery.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04910APA
Koliaki, Chrysi; Liatis, Stavros; Dalamaga, Maria; Kokkinos, Alexander. (2020). The Implication of Gut Hormones in the Regulation of Energy Homeostasis and Their Role in the Pathophysiology of Obesity.. Current obesity reports, 9(3), 255-271. https://doi.org/10.1007/s13679-020-00396-9
MLA
Koliaki, Chrysi, et al. "The Implication of Gut Hormones in the Regulation of Energy Homeostasis and Their Role in the Pathophysiology of Obesity.." Current obesity reports, 2020. https://doi.org/10.1007/s13679-020-00396-9
RethinkPeptides
RethinkPeptides Research Database. "The Implication of Gut Hormones in the Regulation of Energy ..." RPEP-04910. Retrieved from https://rethinkpeptides.com/research/koliaki-2020-the-implication-of-gut
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.